EN DE

Physitrack PLC (PTRK) Fair Value & Analysis

Healthcare · SE · Market cap 125M SEK

PP Physitrack PLC PTRK · ST
Pricekr 9.06
Fair Valuekr 5.78
Upside-36.2%
Quality61/100
Watch Physitrack PLC for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -61.6% net margin
Low debt · generates free cash flow
Ranks above peers (8/12)
Narrow moat 23/100
Evidence: Medium Range kr 4.28 – kr 7.28 Share as image

Fair value as of: Jul 17, 2026

From 13 valuation models · updated 24 days ago

Fair value updated Jul 17, 2026, revised from kr 2.75 to kr 5.78 (+110.2%) since Jun 24, 2026. Share price +19.2% over the past month.

A solid business, but screening 36% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (kr 7.28). The favourable scenario is already priced in.
  • Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

kr 70.00 kr 7.36 Fair Value kr 5.78 Jun 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

60‑month range kr 7.36 – kr 70.00 · fair‑value band kr 4.28 – kr 7.28 · the kr 9.06 price screens above the kr 5.78 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Physitrack PLC (PTRK) currently trades at kr 9.06, while our model-based Fair Value estimate is kr 5.78, implying the stock looks roughly 36.2% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Physitrack PLC generated revenue of 13.6M SEK at a net margin of -61.6%. Revenue grew 3.3% year over year. It earns a return on equity of -43.0%. Net debt stands at 3.3M SEK. Fundamentals as of Jul 17, 2026

Our scenario range runs from kr 4.28 (bear case) to kr 7.28 (bull case); at kr 9.06, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -36%, PTRK screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (kr 0.0300 to kr 5.87). Read the values as a conservative anchor, not as a price target.
Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF kr 2.43 kr 4.04 kr 6.57 80
Rev-Margin DCF kr 1.09 kr 1.60 kr 2.71 74
ROIC Compounder kr 0.0300 kr 0.0500 72
All 13 models by family
DCF Models
FCF DCF kr 2.61 kr 3.73 kr 7.02 38
5Y Revenue Exit kr 0.9900 kr 1.37 kr 2.12 39
5Y EBITDA Exit kr 2.78 kr 4.98 kr 9.28 41
10Y Revenue Exit kr 1.58 kr 2.59 kr 2.90 36
10Y EBITDA Exit kr 2.71 kr 5.87 kr 11.26 37
Earnings-Based
EPV kr 0.0300 kr 0.0500 59
Multiples
EV/EBIT kr 0.2000 kr 0.3400 kr 0.4700 53
EV/EBITDA kr 2.88 kr 3.90 kr 4.93 54
EV/Revenue kr 0.0900 kr 0.2100 kr 0.3400 43
Asset-Based
NCAV (Graham) kr 0.3100 kr 0.4100 kr 0.6100 50
Growth DCF
Growth DCF kr 2.43 kr 4.04 kr 6.57 80
Rev-Margin DCF kr 1.09 kr 1.60 kr 2.71 74
Economic Profit
ROIC Compounder kr 0.0300 kr 0.0500 72

Widest divergence: DCF Models (kr 3.73) versus Earnings-Based (kr 0.0300). Highest evidence: Growth DCF (80).

Notify me when PTRK reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 13.6M SEK
Revenue growth (YoY) +3.3%
Net margin -61.6%
Return on equity -43.0%
Free cash flow 3.9M SEK FY2025
Operating margin 7.7%
More key figures
EPS (TTM) kr -4.47
EPS growth (YoY) +482%
Net debt 3.3M SEK FY2025

Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 61/100

Of which business quality 61 · Market factors (momentum, volatility) 31

Profitability 11
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 98
Earnings quality: real cash, not paper profit
Fin. Strength 55
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 56
Calm price path (market factor)
Momentum 28
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Physitrack PLC, together with its subsidiaries, provides digital healthcare solutions in the United Kingdom, Europe, North America, and internationally. It operates through two segments, Lifecare and Wellness.

Full company description

Physitrack PLC, together with its subsidiaries, provides digital healthcare solutions in the United Kingdom, Europe, North America, and internationally. It operates through two segments, Lifecare and Wellness. The company offers Physitrack, a remote therapeutic monitoring platform that provides a suite of tools for exercise program prescription, patient-reported adherence and tracking, and telehealth for private practices, occupational health and case management, healthcare systems and hospitals, and sports. It also offers Physiapp, a mobile application that allows physiotherapists to deliver personalized rehabilitation programs, track patient progress, and adjust treatments in real-time; and Physiocourses, an e-learning library for healthcare professionals. Physitrack PLC was incorporated in 2012 and is based in London, the United Kingdom.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Physitrack PLC reported revenue of kr 13.8M in FY2025 versus kr 7.8M in FY2021, a compound +15.2%/yr. Reported net income was −kr 6.9M in FY2025.

Growth Quality 61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
13.8M SEK
Latest YoY
−14.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.3%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+18.8%
Avg. growth/yr (11Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+78.4%
Revenue +15.2%/yr
FY21 kr 7.8M
FY22 kr 12.5M
FY23 kr 15.2M
FY24 kr 16.2M
FY25 kr 13.8M
Net income
FY21 −kr 815K
FY22 kr 92.3K
FY23 kr 3.2M
FY24 −kr 6.5M
FY25 −kr 6.9M

PTRK screens 36% overvalued. Compare with Veeva Systems Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Physitrack PLC Fair Value". https://www.fairvalue-calculator.com/stock/PTRK

Peer Group

Health Information Services · 126 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 61 · Above median
Fair Value upside −36% · Above median
Return on assets 2% · Above median
Net margin (TTM) -62% · Bottom 25%
Operating margin (TTM) 8% · Above median
Revenue growth 3% · Below median
Debt / equity 0.40× · Higher than 75% of peers

Valuation Multiples vs Health Information Services median · lower = cheaper

P/B 1.32× · Cheaper than median
P/S (TTM) 0.96× · Cheaper than median
P/FCF 3.4× · Cheaper than 75% of peers
EV/EBITDA 3.5× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 17 · sector 33
PAST 0 · sector 8
HEALTH 80 · sector 98
DIVIDEND 0 · sector 35

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $190.12 $95.12 -50%
Pro Medicus Limited PME A$194.84 A$23.74 -88%
BrightSpring Health Services, Inc BTSG $68.16 $21.31 -69%
HealthEquity, Inc HQY $97.67 $56.63 -42%
Hinge Health, Inc HNGE $88.80 $24.03 -73%
10x Genomics, Inc TXG $45.75 $17.18 -62%
Waystar Holding WAY $22.69 $12.86 -43%
Doximity, Inc DOCS $22.21 $17.18 -23%
Privia Health Group PRVA $28.10 $5.30 -81%
Inventurus Knowledge Solutions Limited IKS ₹1,846 ₹860.28 -53%

Compare Physitrack PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Physitrack PLC (PTRK) overvalued or undervalued?
As of Jul 17, 2026, our model estimates a fair value of kr 5.78 versus a price of kr 9.06, about −36% (overvalued).
What is the fair value of PTRK?
Our model-based fair value for Physitrack PLC is kr 5.78 (as of Jul 17, 2026), built from audited fundamentals. The current price is kr 9.06.
What is the quality score of PTRK?
Physitrack PLC has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Physitrack PLC (PTRK)?
Physitrack PLC reported trailing-twelve-month revenue of about 13.6M SEK (latest available figure, as of Jul 17, 2026).
What is the net profit margin of PTRK?
The net profit margin of Physitrack PLC is about -61.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Physitrack PLC and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.